These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 26008219

  • 1. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.
    Quesada PR, Esteban LL, García JR, Sánchez RV, García TM, Alonso-Vega GG, Ferrández JS.
    Int J Clin Pharm; 2015 Oct; 37(5):865-72. PubMed ID: 26008219
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
    Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, Gatanaga H, Oka S.
    AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
    [Abstract] [Full Text] [Related]

  • 4. Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
    Chikwapulo B, Ngwira B, Sagno JB, Evans R.
    Int J STD AIDS; 2018 Jun; 29(7):650-657. PubMed ID: 29334883
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Mulenga L, Musonda P, Mwango A, Vinikoor MJ, Davies MA, Mweemba A, Calmy A, Stringer JS, Keiser O, Chi BH, Wandeler G, IeDEA-Southern Africa.
    Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
    [Abstract] [Full Text] [Related]

  • 8. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea.
    Lee JE, Lee S, Song SH, Kwak IS, Lee SH.
    Korean J Intern Med; 2019 Mar; 34(2):409-417. PubMed ID: 29020764
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K, Kinai E, Honda H, Yazaki H, Tanuma J, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Oka S.
    AIDS; 2014 Aug 24; 28(13):1903-10. PubMed ID: 25259702
    [Abstract] [Full Text] [Related]

  • 11. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
    Trinh S, Le AK, Chang ET, Hoang J, Jeong D, Chung M, Lee MH, Wang U, Henry L, Cheung R, Nguyen MH.
    Clin Gastroenterol Hepatol; 2019 Apr 24; 17(5):948-956.e1. PubMed ID: 30130625
    [Abstract] [Full Text] [Related]

  • 12. Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
    Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L.
    Trop Med Int Health; 2015 Apr 24; 20(4):518-26. PubMed ID: 25442109
    [Abstract] [Full Text] [Related]

  • 13. Renal function in Ethiopian HIV-positive adults on antiretroviral treatment with and without tenofovir.
    Yilma D, Abdissa A, Kæstel P, Tesfaye M, Olsen MF, Girma T, Ritz C, Friis H, Andersen ÅB, Kirk O.
    BMC Infect Dis; 2020 Aug 06; 20(1):582. PubMed ID: 32762646
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Renal Dysfunction during Tenofovir Use in a Regional Cohort of HIV-Infected Individuals in the Asia-Pacific.
    Tanuma J, Jiamsakul A, Makane A, Avihingsanon A, Ng OT, Kiertiburanakul S, Chaiwarith R, Kumarasamy N, Nguyen KV, Pham TT, Lee MP, Ditangco R, Merati TP, Choi JY, Wong WW, Kamarulzaman A, Yunihastuti E, Sim BL, Ratanasuwan W, Kantipong P, Zhang F, Mustafa M, Saphonn V, Pujari S, Sohn AH, TREAT Asia HIV Observational Databases (TAHOD).
    PLoS One; 2016 Aug 06; 11(8):e0161562. PubMed ID: 27560968
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
    Palacios R, Hidalgo C, Ríos MJ, Rivero A, Muñoz L, Lozano F, Gutiérrez-Ravé V, Gálvez MC, del Arco A, Santos J.
    Eur J Clin Microbiol Infect Dis; 2009 Apr 06; 28(4):399-402. PubMed ID: 18841401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.